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Lithium is a mood stabilizing agent commonly used for the treatment of bipolar disorder.
Here, we investigated the potential neuroprotective effect of lithium against paraquat
toxicity and its underlying mechanisms in vitro. SH-SY5Y human neuroblastoma cells
were treated with paraquat (PQ) 0.5mM concentration after lithium pretreatment to
test lithium’s capability in preventing cell toxicity. Cell death was evaluated by LDH,
WST-8, and tryphan blue assays. Apoptosis was analyzed using DNA fragmentation,
Annexin V immunostaining, Sub G1 cell cycle analysis, and caspase-3 activity assays.
BCL2, BAX, and NRF2 protein expression were evaluated by Western-blotting and the
BDNF protein level was determined with ELISA. mRNA levels of BCL2, BAX, BDNF,
and NRF2 target genes (HO-1, GCS, NQO1), as well as miR-34a expression were
analyzed by qPCR assay. Functional experiments were done via transfection with NRF2
siRNA and miR-34a mimic. Lithium treatment prevented paraquat induced cell death
and apoptosis. Lithium treated cells showed increased anti-apoptotic protein BCL2
and decreased pro-apoptotic protein BAX expression. Lithium exerted a neurotrophic
effect by increasing BDNF protein expression. It also diminished reactive oxygen species
production and activated the redox sensitive transcription factor NRF2 and increased its
target genes expression. Knockdown of NRF2 abolished neuroprotective, anti-apoptotic,
and anti-oxidant effects of lithium. Furthermore, lithium significantly decreased both basal
and PQ-induced expression of miR-34a. Transfection of miR-34a specific mimic reversed
neuroprotective, anti-apoptotic, and anti-oxidant effects of lithium against PQ-toxicity.
Our results revealed two novel mechanisms of lithium neuroprotection, namely NRF2
activation and miR-34a suppression.
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Introduction
Lithium is a mood-stabilizing agent widely used for treatment of acute episodes as well
as for long-term relapse prevention in patients with bipolar disorder (BD), an illness
with evident abnormalities in brain pointing at a neurodegenerational process or represent
disturbed neuronal development (Cousins and Grunze, 2012; Diniz et al., 2013; Malhi et al.,
2013). Apart from mood stabilization, neuroprotective and neurotrophic effects of lithium
have been identified in clinical, preclinical, and in vitro studies (Forlenza et al., 2014).
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A wide variety of in vivo and in vitro studies confirmed
neuroprotective effect of lithium against various insults (Pasquali
et al., 2010; Diniz et al., 2013), thus rendering a potential for
lithium in treatment of chronic neurodegenerative disorders such
as Alzheimer’s disease, Parkinson’s disease (PD), Amyotrophic
lateral sclerosis, and Huntington’s disease.
Lithium’s mechanism of action is still not clear; however, it is
known to modulate neurotransmitter release, reduces oxidative
stress and apoptosis, and induces angiogenesis, neurogenesis,
and neurotrophic responses (Forlenza et al., 2014). Lithium
exerts its biological effects via multiple signaling pathways.
Inhibition of glycogen synthase kinase 3beta (GSK-3β) and
inositol monophosphatase (IMPase), decreased the expression
of the pro-apoptotic protein BAX and increased the expression
of the anti-apoptotic protein BCL-2, activation of the cell
survival kinases and increased expression of such neurotrophic
factors brain-derived neurotrophic factor (BDNF) are well-
known effects of lithium (Forlenza et al., 2014).
Paraquat (PQ) is widely used as an herbicide to control
weeds (Moretto and Colosio, 2013; Goldman, 2014). Several
epidemiologic studies suggest that the subacute exposure to
PQ increases the incidence rate of PD in humans (Jenner
et al., 2013; Goldman, 2014). In addition, PQ administration to
rodents induces various features of PD, including motor deficits,
dopaminergic neuronal loss and α-synuclein aggregation (Blesa
et al., 2012). Therefore, PQ toxicity may be considered as a
useful model to study dopaminergic cell death associated with
PD. The definite mechanism of PQ neurotoxicity is not fully
understood. However, several mechanisms have been implicated
such as mitochondrial complex I inhibition and increase in
reactive oxygen species (ROS) formation (Moretto and Colosio,
2013).
Oxidative stress plays a major role in the degeneration of
dopaminergic neurons in PD (Dias et al., 2013). One of the
neuroprotective strategies may be to prevent oxidative stress via
activation of antioxidant defense systems. The nuclear factor
erythroid 2-related factor 2 (NRF2) is a key transcription
factor that activates anti-oxidant response element (ARE)
containing anti-oxidant genes including heme oxygenase-1 (HO-
1), peroxiredoxin (PRX), NAD(P)H:quinone oxidoreductase
1 (NQO1), glutamatecysteine ligase (GCL), and glutathione
peroxidase (GPX) (Milani et al., 2013; Gan and Johnson, 2014).
NRF2 deficiency increases MPTP sensitivity in mice whereas
NRF2 overexpression protects againstMPTP toxicity (Chen et al.,
2009b).
MicroRNAs (miRNAs), are short, single stranded,
endogenous, non-coding RNAs which have been discovered in
1993 (Lee et al., 1993). They regulate gene expression by targeting
the 3′ UTR region of their target mRNAs via degradation or
translational repression (Stroynowska-Czerwinska et al.,
2014). MicroRNAs can control most biological processes
including development, cell cycle, apoptosis, differentiation, and
angiogenesis (Tüfekci et al., 2014). Several miRNAs exhibiting
brain-specific expression and have been reported to be associated
with physiological and pathological processes in the brain (Sun
and Shi, 2014). MiRNA microarray studies showed that several
miRNAs expression altered in PD patients’ brain and blood
samples (Miñones-Moyano et al., 2011; Vallelunga et al., 2014;
Serafin et al., 2015). Peripheral miRNAs expression changes
could be used for differential diagnosis of PD from Multiple
System Atrophy (Vallelunga et al., 2014). Additionally, Anti-
parkinsonian drugs alter blood miRNAs expression (Serafin
et al., 2015). Besides, neurotoxins such as PQ cause miRNA
expression changes in neuronal cells (Narasimhan et al., 2014).
Additionally, lithium regulates the expression of some miRNAs
and these may play a role in lithium’s neuroprotective effects
(Chen et al., 2009a).
In the present study we examined the protective effect of
lithium on PQ neurotoxicity and its mechanisms in human
SH-SY5Y cell line.
Materials and Methods
Cell Culture
SH-SY5Y cells were maintained in Dulbecco’s Modified
Eagle Medium: Nutrient Mixture F-12 (DMEM:F12) (Gibco,
Gaithersburg, MD) supplemented with heat-inactivated
fetal bovine serum (10% v/v), L-glutamine (1% v/v) and
penicillin-streptomycin (1% v/v) at 37◦C in 5% CO2.
Lactate Dehydrogenase Release Assay
The effects of lithium on PQ-induced cytotoxicity were measured
by LDH release assay using Cytotoxicity Detection KitPLUS
(Roche Diagnostics, Germany) according to the manufacturer’s
protocol.
WST-8 Assay
Cell viability was assessed by the ability of viable cells to reduce
WST-8 reagent. Following treatment, 10µL of WST-8 reagent
were added to each well-containing 100µL of medium and
the plate was incubated for 4 h at 37◦C. Afterwards, the light
absorbance of each well was measured on a microplate reader
(Biotek, USA) at 450 nm. Cell viability was expressed as a
percentage of the untreated cells.
Trypan Blue Staining
Cell death was also evaluated by trypan blue staining. After
incubation, cells were stained with trypan blue stain for 1min,
and stained cells were photographed by using an inverted
microscope (Olympus IX41, Japan).
DNA Fragmentation Assay
Cell Death Detection ELISA Kit was used to evaluate DNA
fragmentation in the cytoplasm of apoptotic cells. The data are
expressed as fold increase in optical density as compared with
control treated cells.
Measurement of Sub-G1 DNA Content
At the end of treatment, cell pellets were resuspended in DNA
staining reagent containing 50µl RNAse (50µg/ml) and 450µl
propidium iodide (100µg/ml) and incubated for 15min at room
temperature. A total of 10,000 cells in each sample were analyzed
and the percentage of apoptotic cells accumulated in the sub-
G1 peaks were determined by using the FACS Canto II analyzer
(Becton Dickinson, USA).
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Annexin V Immunostaining
Annexin V-FITC apoptosis detection kit I (Becton Dickinson,
USA) was used to detect apoptotic cells. After staining procedure,
cells were fixed with 4% paraformaldehyde for 20min. Stained
cells were photographed by using an inverted microscope
(Olympus BX50, Japan).
Caspase-3 Activity
Caspase-3 activity was measured as an indicator of apoptosis
using colorimetric caspase activity assay kit (Invitrogen, USA)
according to manufacturer’s protocol.
Intracellular ROS Quantification
After 24 h lithium (2mM) incubation period, supernatant
was discarded and the cells were incubated with 100µl PBS
containing 10µM CM-H2DCFDA for 1 h. Afterwards, CM-
H2DCFDA was removed from each well and cells were treated
with PQ (500µM) or both PQ (500µM) and lithium for 24 h.
Fluorescence (at 520 nm) of dichlorofluorescein (DCF) in the
supernatant was measured in response to excitation at 492 nm by
using a microplate reader (Varioskan, Thermo).
Quantitative PCR for mRNAs
Total RNA was isolated by using the Nucleospin RNA II
Kit (Macherey-Nage, Germany) and converted to cDNA with
RevertAid First Strand cDNA Synthesis Kit (Thermo Fermentas,
ABD). Real-time quantitative PCR (qPCR) was performed using
the Lightcycler 1.5 Instrument (Roche Diagnostics, Germany)
and the SYBR-Green I kit according to the manufacturer’s
instructions. The primers used in the qPCR reactions are listed in
Supplementary Table 1. The relative expression levels of mRNAs
were quantified by using the 2−11 Ct method.
Western Blot Analysis
After treatment, cells were harvested, and total or fractionated
protein was isolated from SH-SY5Y cells. Equal amounts of
protein were resolved by 10–12% SDS–PAGE, transferred to a
PVDF membrane and blocked with 3% BSA. Antibody dilution
in immunoblotting was performed as follows: anti-NRF2 (1:250),
anti-BCL-2 (1:500), anti-BAX (1:500), Lamin A/C(1:1000), and
actin (1:1000). Immunodetection was measured using enhanced
chemiluminescence (SuperSignal West Pico, Thermo Fisher
Scientific, USA) according to the manufacturer’s instructions.
The resulting bands were analyzed with densitometer (UVP Gel
Imager System, CA) and measured intensities of corresponding
actin bands were used as cytoplasmic or total protein loading
control while lamin A/C was used as nuclear loading control.
Transfection for NRF2 siRNA
Small interfering RNA experiments were performed by
using human-specific NRF2 or non-targeting siRNA (On-
TargetPlus SMART pool human NFE2L2; Dharmacon).
Cells were transfected with 50 nM siRNA, using Dharmafect
reagent (Thermo Scientific), according to the manufacturer’s
instructions.
Real-time PCR Analysis of miR-34a
Total RNA was isolated from cells using Qiagen miRNeasy Mini
Kit. Then, 2µg RNA was reverse-transcribed using miScript II
RT Kit (Qiagen, Valencia, CA). Real-time qPCR was performed
using miScript SYBR Green PCR Kit on a Lightcycler R© 480 Real-
Time PCR System (Roche Diagnostics, Germany). Primer for
maturemiR-34a, SNORD95 andU6were purchased fromQiagen
(Valencia, CA). The relative expression levels of miRNAs were
normalized to that of internal controls U6 and SNORD95 snRNA
by using the 2−11 Ct method.
miR-34a Target Gene and Pathways Analysis
BDNF 3′UTRs were collected from ENSEMBL (Flicek et al.,
2013) from its 10 available alternative versions which lead to
4 different 3′UTRs. RNA22 version 2 (Miranda et al., 2006),
PITA (Kertesz et al., 2007), and TargetScan version 6 (Ruby
et al., 2007) were used to predict miR-34a target binding sites
within the 3′UTRs. Additionally, TarBase (Ruby et al., 2007)
and miRTarBase (Hsu et al., 2011) were screened for miR-34a
targets.
Reactome (D’Eustachio, 2011) was used for the pathway
analysis of the miR-34a targets (4142 without duplicates)
available on TarBase (477) and miRTarBase (4700) with BDNF
added (Supplementary Table 2).
Transfection with miRNA Mimics and Inhibitor
The miR-34a mimic, inhibitor and a negative control mimic
were purchased from Qiagen. Transfections of cells with mimics
(50 nM) were performed using HiPerFect Transfection Reagent
(Qiagen, Valencia, CA). Total RNA from samples were isolated
after 48 h of transfection for quantification of miRNA and target
genes’ expression.
BDNF ELISA
The BDNF content in the culture medium was measured using
BDNF ELISA Kit (Boster Biomedical, China) according to the
manufacturer’s protocol.
Neurite Outgrowth and Neurite Length
After transfection, serum-starved cells were treated with
lithium and PQ and they were photographed with inverted
phase-contrast microscope (Olympus CX41, Japan) at 40X
magnification. All experiments were performed in triplicate.
At least 30 neurites were analyzed for each sample. Neurite
outgrowth was quantified by calculating the number of processes
per cell. Neurite length was measured using the Image J software
(NIH, USA) and expressed as mean process length. A neurite was
defined as a cell process longer than 10µm.
Statistical Analysis
Statistical analyses were performed with SPSS 18.0. Values
represent the mean ± standard error of the mean (SEM).
Comparison of two groups was analyzed by using the Mann-
Whitney U test. P values smaller than 0.05 were considered to
be statistically significant.
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Results
Lithium Protects SH-SY5Y Cells from
PQ-induced Cell Death
First, we examined lithium cytotoxicity by LDH and WST-8
assays. Concentrations of lithium up to 10 mM did not result
in an increased rate of cell death, but higher doses (> 10mM)
of lithium were toxic to SH-SY5Y cells (Figures 1A,B). Lithium
treatment at 2mM concentration did not decrease cell viability
during 24–72 h incubation periods (Figure 1C). PQ alone
increased cell death in SH-SY5Y cells in a dose and time
dependent fashion (Figures 1D,E).
Next, we evaluated lithium effect on cell viability. PQ
treatment significantly decreased cell viability (73.6 ± 2.6%).
Lithium pre-treatment (2–5mM) increased cell viability to 80.3
and 78.9%, respectively (Figure 1F).
FIGURE 1 | Lithium decreases paraquat toxicity in SH-SY5Y cells.
Cells were treated with different doses of lithium (0.5–50mM) for 24 h. Upon
lithium treatment, (A) cell viability was quantified by WST-8 assay and (B,C)
percentage of cell death was analyzed by LDH release assay. 10mM and
higher doses of lithium significantly reduced cell viability. PQ toxicity in
SH-SY5Y cells is (D) dose and (E) time dependent. SH-SY5Y cells were
treated with lithium (2–5mM) for 24 h and then incubated with 0.5mM PQ for
a further 24 h. (F) Cell viability was quantified by WST-8 assay and (G) cell
death was determined by LDH release assay. PQ treatment increased cell
death and lithium reversed the toxic effect of PQ in SH-SY5Y cells.
Representative light microscopy images (H,I) of trypan blue staining showed
the neuroprotective effect of lithium against PQ-induced cell death. The data
are presented as mean ± standard error (S.E), n = 5. (*p < 0.05 compared to
control and #p < 0.05 compare to PQ treated cells).
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Lithium effect on PQ-induced cell damage was further
investigated using LDH release assay. PQ treatment increased
LDH release from SH-SY5Y cells (14.4 ± 0.3%). Pretreatment
with 2–5mM lithium reduced the LDH release to 7.3 ±
0.2 and 9.5 ± 0.3%, respectively (Figure 1G). However, 24 h
pretreatment with 10mM lithium had no effect on PQ-induced
cytotoxicity.
The effect of lithium on cell death was further confirmed
by trypan blue staining. PQ treatment significantly increased
the percentage of cells stained with trypan blue (Figures 1H,I).
On the contrary, lithium pretreatment significantly reduced the
percentage of cells stained with trypan blue.
Lithium Decreases PQ-induced Apoptosis in
SH-SY5Y Cells
Our results showed a significant 2.4-fold increase in DNA
fragmentation upon 48 h of PQ treatment (Figure 2A).
FIGURE 2 | Lithium reduces apoptotic cell death induced by PQ in
SH-SY5Y cells. (A) DNA fragmentation was increased with 0.5mM PQ
treatment, which was analyzed by Cell Death ELISA assay. (B) Lithium (2mM
and 5mM) pretreatment reduces DNA fragmentation induced by PQ in
SH-SY5Y cells. (C) Apoptotic cells were stained by Annexin-V-FITC dye and
visualized using immunofluorescence microscopy. (D) Flow cytometric
analysis of the sub G1 apoptotic population was assessed by using PI
staining. Lithium attenuates PQ induced increase of sub G1 apoptotic
population in SH-SY5Y cells (E). Caspase-3 activity was evaluated in lysates
of treated cells by spectrophotometric detection of the chromophore
p-nitroaniline (pNA) formed after cleavage from the labeled substrate
DEVD-pNA. Lithium reduced PQ induced caspase-3 activity increase in
SH-SY5Y cells. The data are presented as mean ± S.E, n = 5. (*p < 0.05
compared to control and #p < 0.05 compare to PQ treated cells).
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Pretreatment with lithium attenuated PQ induced DNA
fragmentation significantly (Figure 2B).
Lithium effect on apoptosis was evaluated by Annexin-V
immunostaining. PQ treatment markedly increased the annexin
V-positive cells and this increase was prevented by lithium
pretreatment (Figure 2C).
Next, we analyzed the effect of lithium on PQ-induced
apoptosis by assessing the sub-G1 cells in PI-stained samples
of SH-SY5Y cells by flow cytometry. We observed a significant
increase in sub-G1 cells population (78.6%) after 48 h PQ
treatment while treatment with 2mM lithium decreased the ratio
of sub-G1cells to 47.8% (Figure 2D).
We also measured the activity of caspase-3 as an indicator of
apoptosis. PQ-treatment for 24 h at a dose of 0.5mM significantly
increased the caspase-3 activity. Lithium pretreatment prevented
PQ-induced increase in caspase-3 activity (Figure 2E).
Lithium Reverses the Expressions of BCL-2
Family Genes Altered by PQ
As shown in Figure 3A, lithium treatment alone significantly
increased BCL-2 mRNA expression at 12 h. PQ treatment
also increased BCL-2 mRNA expression 1.7 fold compared
to control cells. Additionally, lithium pretreatment resulted
FIGURE 3 | Lithium modulates BCL-2 family genes levels in SH-SY5Y
cells. SH-SY5Y cells were pretreated with lithium (2mM) for 12 h before
0.5mM of PQ incubation. Intracellular (A) BCL-2 and (B) BAX mRNA levels
were quantified by qPCR. Both PQ and lithium treatment increased the
BCL-2 mRNA level. PQ treatment increased the BAX mRNA level and lithium
pretreatment reversed PQ’s effect on the BAX mRNA level. (C) Ratio of
BCL-2 to BAX mRNA levels was markedly reduced by PQ treatment and
lithium pretreatment increased this ratio. Intracellular (D,E) BCL-2 and (D,F)
BAX protein levels were analyzed by western blot and actin was used as a
loading control. The intensity of proteins were quantified by using Image J
(NIH Bethesda). (G) Ratio of BCL-2 to BAX was markedly reduced by PQ
treatment whereas lithium pretreatment increased this ratio. The data are
presented as mean ± S.E, n = 5. (*p < 0.05 compared to control and
#p < 0.05 compare to PQ treated cells).
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in further increase of BCL-2 mRNA expression in SH-SY5Y
cells.
The expression of BAX mRNA increased 2.6-fold after PQ
treatment in SH-SY5Y cells. Lithium pretreatment reduced BAX
mRNA expression induced by PQ. Lithium alone also decreased
BAX mRNA expression in SH-SY5Y cells (Figure 3B).
In addition, the BCL-2 / BAX mRNA expression ratio
was markedly reduced upon PQ treatment while lithium
pretreatment significantly increased this ratio (Figure 3C).
Consistent with gene expression analysis, lithium treatment
increased BCL-2 protein level 1.9 fold, but PQ treatment did not
alter the BCL-2 protein level in SH-SY5Y cells (Figures 3D,E).
BCL-2 protein expression also increased in Lithium and PQ
treated cells (Figures 3D,E). Lithium alone decreased BAX
protein levels (0.42 fold) in SH-SY5Y cells. BAX protein level
increased 1.7 fold after PQ exposure while lithium pretreatment
prevented PQ induced BAX protein increase in SH-SY5Y
cells (Figures 3D,F). Additionally, the BCL-2/ BAX protein
expression ratio was markedly reduced upon PQ treatment
while lithium pretreatment significantly increased this ratio
(Figure 3G).
Lithium Alters PQ-associated Decrease in BDNF
mRNA Expression and Secretion
Our results showed that lithium alone increased BDNF mRNA
expression by 2.7 fold whereas PQ treatment caused a 0.62-fold
reduction in BDNF mRNA expression compared to control cells.
Lithium pretreatment prevented the decrease in BDNF mRNA
levels after treatment with PQ (Figure 4A).
Consistent withmRNA results, lithium treatment significantly
increased BDNF secretion compared to control groups.
Furthermore, PQ-associated decrease in BDNF levels was
prevented by lithium pretreatment (Figure 4B).
Lithium Diminishes PQ-induced ROS Production
in SH-SY5Y Cells
As shown in Figure 5A, PQ induced ROS production (156.8 ±
6.9 %) and pretreatment with lithium caused a significantly
decrease ROS production induced by PQ (121.9 ± 4.9 %)
compared to only PQ treated cells.
Lithium Triggers Nuclear Translocation and
Activation of NRF2 Transcription Factor in
SH-SY5Y Cells
Nuclear translocation of NRF2 transcription factor is considered
to be an important mechanism for its activation. Western
blot analysis demonstrated that translocation of NRF2 was
significantly increased by 24 and 48 h lithium treatment
(Figures 5B,C).
We then examined the effect of lithium on mRNA
expression of NRF2 and NRF2 -regulated genes including
Heme-oxygenase-1 (HO-1), NAD(P)H: quinone oxidoreductase
(NQO1), glucosylceramide synthase (GCS). As a shown in
Figure 5D, The expression of NRF2 mRNA was increased after
24 h lithium treatment and this increase was maintained up
to 72 h. Furthermore, we found that 72 h lithium treatment
increased mRNA levels of NRF2 target genes (Figures 5E–G).
Knockdown NRF2 Expression with siRNA Inhibits
its Target Genes’ Expression
To confirm the repression by NRF2 specific siRNA, we
evaluated NRF2 mRNA expression by qPCR and NRF2
FIGURE 4 | Lithium increases BDNF expression and secretion in
SH-SY5Y cells. Cells were pretreated with lithium (2mM) for 24 h
prior to PQ exposure. (A) Intracellular BDNF mRNA levels were
quantified by real time qPCR. PQ exposure markedly reduced the
BDNF mRNA level while lithium pretreatment reversed the PQ effect
on the BDNF mRNA level. (B) Secreted BDNF protein levels in culture
medium were measured by BDNF ELISA kit. Lithium increased PQ
induced BDNF decrease in SH-SY5Y cells. The data are presented as
mean ± S.E, n = 5. (*p < 0.05 compared to control and #p < 0.05
compare to PQ treated cells).
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FIGURE 5 | Lithium reduces ROS production and activates the NRF2
pathway. (A) SH-SY5Y cells were pretreated with lithium (2mM) for 24 h
then 0.5mM of PQ was added. Intracellular ROS production was quantified
by using the CM-H2DCFDA. Lithium reduced the PQ induced ROS
production in SH-SY5Y cells. (B) Cells were treated with 2mM lithium for 24,
48 and 72 h. Then, both nuclear and cytoplasmic NRF2 protein levels were
analyzed by Western blot. Actin for cytoplasmic, lamin A/C for nuclear
fractions were used as loading control. (C) The ratio of the integrated density
of nuclear NRF2 to lamin A/C and cytoplasmic NRF2 to actin was quantified
by using Image J (NIH Bethesda). Lithium increased nuclear translocation of
NRF2. (D) NRF2, (E) HO-1, (F) NQO1, and (G) GCS gene expression levels
were quantified by qPCR. Lithium treatment increased mRNA levels of NRF2
target genes. NRF2; nuclear factor erythroid 2-related factor 2, HO-1;
heme-oxygenase-1, NQO1; NAD(P)H: quinone oxidoreductase, and GCS;
glucosylceramide synthase. The data are presented as mean ± S.E, n = 5.
(*p < 0.05 compared to control and #p < 0.05 compare to PQ treated cells).
protein expression by Western blotting. Transfection of
cells with NRF2 siRNA decreased the NRF2 expression at
both mRNA and protein levels (Figures 6A–C). In addition,
NRF2 inhibition significantly reduced the mRNA expression
of NRF2-regulated genes, HO-1, NQO1, GCS, and BCL-2
compared to cells transfected with non-targeting siRNA
(Figures 6D–G).
NRF2 Knockdown Reverses Neuroprotective,
Anti-apoptotic and Anti-oxidant Effects of
Lithium on PQ-Induced Cell Death
We further investigated whether the neuroprotective, anti-
apoptotic, and anti-oxidant effects of lithium were abolished by
siRNA knockdown of NRF2. After transfection, the effect of
lithium on cell viability, apoptosis, and ROS production were
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FIGURE 6 | NRF2 siRNA transfection decreases NRF2 and target
genes mRNA and NRF2 protein expression in SH-SY5Y cells.
Cells were transfected with NRF2 siRNA or non-target siRNA for 24 h.
(A,B) NRF2 protein levels were measured by Western blot, (C) mRNA
levels of NRF2 were evaluated with qPCR. Transfection of cells with
NRF2 siRNA decreased NRF2 mRNA and protein expression.
Knocking-down NRF2 expression reduced the mRNA expression of (D)
HO-1 and (E) NQO1 (F) GCS and (G) BCL-2 determined by qPCR.
The data are presented as mean ± S.E, n = 5. (*p < 0.05 compared
to non-target siRNA transfected cells).
examined with WST-8 assay, DNA fragmentation and CM-
H2DCFDA, respectively. We found that neuroprotective, anti-
apoptotic, and anti-oxidant effects of lithium were abolished
by silencing NRF2 expression with specific siRNA transfection
(Figures 7A–C). These findings suggest that NRF2 activation
has a critical role for the neuroprotective, anti-apoptotic, and
anti-oxidant effects of lithium.
The Effect of Lithium and NRF2 Knockdown on
Neurite Outgrowth
Lithium significantly increased neurite outgrowth in SH-
SY5Y cells. To investigate the role of NRF2 on lithium-
mediated neurite outgrowth, SH-SY5Y cells were transfected
with NRF2 siRNA. We found lithium treatment increased
neurite number per cell and neurite length in control cells
and non-target siRNA transfected cells. PQ treatment alone
decreased neurite outgrowth, whereas lithium pretreatment
reversed this decrease to the control levels (Figures 8A–C).
However, the effect of lithium on neurite outgrowth was
diminished in NRF2 siRNA transfected cells in both basal and
PQ treated conditions. These results suggested that NRF2 could
be involved in the lithium effect on neurite outgrowth in SH-
SY5Ycells.
Lithium Downregulates miR-34a Expression
Induced by PQ
We analyzed the expression of miR-34a by using qPCR.
Our results indicate that lithium treatment alone decreased
miR-34a expression compared to control cells. In addition,
PQ treatment significantly increased miR-34a expression and
lithium pretreatment prevented PQ induced increase of miR-34a
expression (Figure 9A).
The Effects of Up and Down Regulation of
miR-34a Expression on its Target Genes’
Expression
The transfection efficiency of mature miRNAs was assessed by
qPCR. Our results showed that transfection with miR-34a mimic
robustly upregulated miR-34a level 322.5-fold (Figure 9B).
To determine whether overexpressed miR-34a can
downregulate its target genes expression, we investigated
the mRNA levels of BCL-2, NRF2, and BDNF (a predicted target
of miR-34a). Over-expression of miR-34a significantly reduced
the mRNA levels of BCL-2, NRF2, and BDNF in SH-SY5Y cells
(Figures 9C–E).
miR-34a antagomir treatment significantly inhibited basal
mir-34a expression (Supplementary Figure 1A). On the other
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FIGURE 7 | Down-regulation of NRF2 reversed the neuroprotective
and anti-oxidant effects of Lithium. Cells were transfected with
NRF2 siRNA or non-target siRNA. Upon transfection, cells were
pretreated with 2mM lithium prior to 0.5mM PQ treatment. (A) Cell
viability, (B) Apoptosis and (C) ROS production were quantified via
WST-8 assay, Cell Death ELISA and CM-H2DCFDA method, respectively.
Neuroprotective and anti oxidant effects of lithium were reversed by
NRF2 siRNA transfection. The data are presented as mean ± S.E,
n = 5. (*p < 0.05 compared to control and #p < 0.05 compare to PQ
treated cells).
hand, miR-34 antagomir treatment did not cause any significant
increase in BDNFmRNA and protein expression (Supplementary
Figures 1B,C).
The Result of miR-34a Target Gene and
Pathways Analysis
Mir-34a is an intergenic miRNA located on human chromosome
1 between the coding regions for GPR157 and HBPD.
Neither TarBase, nor miRTarBase list BDNF among the
many experimentally confirmed targets of miR-34a. Also,
RNA22 and TargetScan did not return any binding sites for
miR-34a within the 3′UTR of BDNF, suggesting that it does
not affect BDNF expression levels. However, PITA predicted
a borderline interaction (Score: -9.44) between miR-34a-5p
and BDNF (ENST00000499568, ENST00000500662, and
ENST00000502161) and another weaker (Score: -7.17), but
still potentially relevant interaction with BDNF ENSEMBL
transcripts ENST00000439476, ENST00000525528, and
ENST00000395986 (Supplementary Table 3). But, the results
of loss-of-function experiment did not point to a direct
microrna-target interaction between miR-34a and BDNF.
The 4142 non-duplicate identifiers, and 6 synonyms for
BDNF, of miR-34a-5p targets were submitted to Reactome
analysis and 1440 targets were used while Reactome was
not able to map 2248 of them including BDNF and all its
synonyms (Supplementary Table 2). Some of the pathways
enriched in targets of miR-34a-5p have p-values below the
general significance threshold of 0.05 and were selected for
display (Figure 10A). The number of mapped targets for Cellular
Senescence is largest (197) followed by Oxidative Stress (153). If
only the targets shared between TarBase and miRTarBase (237)
and BDNF and its synonyms are submitted to Reactome, a similar
result is achieved with Cellular Senescence and Oxidative Stress
having high prominence (Figure 10B).
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FIGURE 8 | Lithium may exerts neurite outgrowth effect via Nrf2
activation. After NRF2 siRNA or non-target siRNA transfection, SH-SY5Y
cells were treated with 2mM lithium for 24 h prior to 0.5mM PQ
treatment. (A) Neurite cell number was counted using ImageJ 1.42
(http://imagej.nih.gov/ij/). (B) The average maximal neurite length for both,
the transfected and non-transfected cells were analyzed by ImageJ 1.42
(http://imagej.nih.gov/ij/). (C) Representative phase-contrast microscopy
images are shown in order to indicate neurite outgrowth distribution.
Arrowheads indicate the neurites arising from cells. Briefly, lithium
pretreatment increased neurite numbers and length which decreased by
PQ in non-transfected and non-target siRNA transfected groups. Nrf2
knockdown partially reversed the effects of lithium on neurite outgrowth.
At least 30 neurites were analyzed for each sample. Scale bar, 50µm.
The data are presented as mean ± S.E, n = 3. (*p < 0.05 compared to
control, #p < 0.05 compared to PQ treated cells and †p < 0.05
compared to Non-Target siRNA).
Over-expression of miR-34a Reverses the
Neuroprotective and Anti-apoptotic Effects of
Lithium
To investigate the effect of miR-34a on lithium mediated
neuroprotection in SH-SY5Y cells, we used miR-34a mimic
to simulate overexpression of miR-34a. As shown Figure 11A,
lithium significantly increased cell viability and this increase
remained unchanged in negative control mimics transfected
cells. Neuroprotective effect of lithium was reversed by up-
regulation of miR-34a levels with mimic transfection in SH-SY5Y
cells.
The lithium-mediated anti-apoptotic effect was also
significantly reduced in the miR-34a mimic transfected cells as
compared with cells that were transfected with a control mimic
(Figure 11B). Our results indicate the important role of miR-34a
in mediating the neuroprotective effect of lithium.
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FIGURE 9 | Lithium decreases miR-34a expression and miR-34a
overexpression significantly downregulates the expression of
miR-34a target genes in SH-SY5Y cells. (A) Cells were incubated with
lithium or PQ and expression levels of miR-34a were quantified by qPCR.
Lithium treatment decreased miR-34a expression. SH-SY5Y cells were
transfected with miR-34a mimic or negative control (NC) mimic for 48 h and
the cells were collected for RNA isolation. (B) qPCR was performed for
miR-34a to determine the efficiency of transfection and (C–E) mRNA levels of
miR-34a target genes after transfection. miR-34a overexpression
down-regulates BCL-2 and NRF2 and BDNF mRNA levels in SH-SY5Y cells.
Control: cells without any transfection. The data are presented as mean ±
S.E, n = 5. (*p < 0.05 and #p < 0.05 compared to PQ treated cells).
Up-regulation of miR-34a Expression Reverses
the Anti-oxidant Effect of Lithium
We further investigated the role of miR-34a on the anti-oxidant
effect of lithium. SH-SY5Y cells were transfected with miR-34a or
control mimics, then the effects of lithium on the production of
ROS was evaluated using CM-H2DCFDA. The lithium-mediated
antioxidant effect was significantly reduced in miR-34a mimic
transfected cells as compared with cells that were transfected with
control mimics (Figure 11C).
Over-Expression of miR-34a Abolish Neurite
Outgrowth Effect of Lithium in SH-SY5Y Cells
Neurite outgrowth was evaluated after transfection with mimics
to determine the impact of miR-34a on lithium-mediated neurite
outgrowth. While PQ treatment decreased neurite outgrowth,
lithium alone significantly increased neurite number per cell and
length. Lithium pretreatment prevented PQ induced decrease of
neurite outgrowth. This effect of lithium remained unchanged
in negative control mimic transfected cells. However, miR-34a
mimic significantly reduced the neurite outgrowth effect of
lithium (Figures 12A–C).
Discussion
In the present study, the neuroprotective effect of lithium on PQ
toxicity was evaluated in SH-SY5Y cells.
We first investigated lithium effect on cell viability to find
optimum concentration of lithiumwithout cytotoxicity. Previous
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FIGURE 10 | Reactome pathways enriched in targets of miR-34a-5p.
(A) Experimentally confirmed miR-34a-5p targets from miRTarBase and
TarBase were combined and BDNF was added. The target list was
submitted to pathway analysis using EBI’s Reactome. (B) Confirmed targets
of miR-34a-5p shared between miRTarBase and TarBase and therefore likely
more confident, were submitted to Reactome for pathway analysis. Bottom
x-axis show the expected probability for pathway enrichment and upper
x-axis shows the number of targets mapped to the given pathway. Dark gray
bars refer to p-values whereas patterned gray bars indicate the number of
mapped targets. In (A) pathways were selected to be below a p-value of
0.05 (21) whereas the first 20 pathways ordered by p-value were selected for
(B). A comprehensive list can be found in Supplementary Table 2. The
enriched pathways are similar for combined and shared targets from
miRTarBase and TarBase.
studies determined that lithium concentrations of up to 4mM
for 4 days did not decrease viability of SH-SY5Y cells (Allagui
et al., 2009). Additionally, lower dosage (approximately 2.3mM)
of lithium for longer periods (up to 5 days) has no cytotoxic
effect in PC12 cells, a rat pheochromocytoma cell line (Yang
et al., 2014). We chose to use 2mM concentration of lithium at
different time points (24–72 h) for further experiments.
Many recent studies have shown that exogenous
environmental toxins, such as PQ are linked to PD (Tufekci et al.,
2011; Baltazar et al., 2014). Here, we show that PQ is significantly
toxic to SH-SY5Y cells in a time and dose dependent manner
which is consistent with a recent study (Martins et al., 2013). PQ
exposure leads to neuronal cell death in vitro and in vivo; though
exact mechanisms of selective neurodegeneration induced by PQ
in dopaminergic neurons are still unknown (Berry et al., 2010).
In our study, lithium prevented PQ-induced neuronal cell death
and increased cell viability at concentrations of 2–5mM. To our
knowledge, there is no study investigating protective effect of
lithium in PQ induced neuronal death. The neurotrophic effect
of lithium is well-documented in various cultured neuronal cell
systems in vitro. In contrast to neurotoxins, lithium induces
neurite outgrowth and differentiation of various neuronal cells.
Lithium treatment of hippocampal neurons for 5 days increased
dendritic outgrowth at 1–2mM concentration (Park et al.,
2014). In our study, lithium enhanced neurite number and
length as markers of neurite outgrowth in SHSY5Y cells. We
found PQ reduced secretion and mRNA levels of BDNF one
of the main regulators of synaptogenesis and dendritogenesis
(Nelson and Alkon, 2014). Lithium pretreatment rescued BDNF
mRNA and secreted protein level. BDNF is a main partner
for the neurotrophic effects of lithium. Postmortem studies
showed that the BDNF level is decreased in the brain of PD
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FIGURE 11 | Lithium may exert its neuroprotective, anti-apoptotic
and anti-oxidant functions via miR-34a. Mimic transfected (miR-34a
mimic or negative control mimic) and non-transfected cells were treated with
2mM lithium for 24 h prior to 0.5mM PQ treatment. (A) Transfection of
miR-34a mimic diminished the neuroprotective effect of lithium against
PQ-toxicity. Overexpression of miR-34a also reversed the (B) anti-apoptotic
and (C) anti-oxidant effects of lithium on SH-SY5Y cells. (*p < 0.05
compared to control and #p < 0.05 compared to PQ treated cells).
patients especially in the substantia nigra region (Allen et al.,
2013). PQ administration to mice also reduces BDNF level in
the hippocampus region of the brain (Litteljohn et al., 2011).
Treatment of rat cortical neurons with lithium for 6 days induced
protein expression of BDNF (Hashimoto et al., 2002). Chronic
treatment of rats with lithium for 14–28 days also increased
BDNF expression in the hippocampus and temporal cortex
(Fukumoto et al., 2001).
There is powerful evidence in human studies to support the
role of oxidative stress in PD. It has been demonstrated that
alteration of oxidative stress markers in serum and cerebrospinal
fluid samples of PD patients (Buhmann et al., 2004). Post-
mortem studies showed an increase in ROS production and a
reduction in antioxidants such as glutathione in dopaminergic
neurons (Dias et al., 2013). Deficiencies of mitochondrial
complex I in the brain have also been shown in post-mortem
PD studies (Subramaniam and Chesselet, 2013). Mutations in
PD causing genes including parkin, α-synuclein, PTEN induced
putative kinase 1, and DJ-1 also cause mitochondrial dysfunction
leading to excessive production of ROS (Blandini, 2013; Guo
et al., 2013; Zuo and Motherwell, 2013). PQ, as a redox
cycling agent, exerts its cytotoxic effect by generating ROS
including superoxide radical, hydrogen peroxide, and hydroxyl
radicals and inhibits mitochondrial Complex I and Complex
III function (Blanco-Ayala et al., 2014). PQ induced oxidative
stress also leads to mitochondrial dysfunction. Here, as a
measure of mitochondrial functioning, WST-8 assay showed
PQ induced mitochondrial dysfunction which was significantly
reversed by lithium pretreatment. Consistent with a previous
study (Cristóvão et al., 2009), our findings also confirmed
that PQ treatment induced oxidative stress in SH-SY5Y cells.
Lithium pretreatment reversed PQ induced ROS production
as shown by DCF analysis. Following the various pathogenic
mechanisms such as mitochondrial dysfunction, oxidative stress,
dysregulated calcium metabolism, misfolded protein responses,
endoplasmic reticulum stress, and dysregulated autophagy, the
final common step in neurodegenerative diseases is neuronal
cell death. Apoptosis is the dominant mode of cell death in PD
(Ghavami et al., 2014). Lithium’s anti-apoptotic action is well-
known and responsible for its therapeutic effect (Chiu et al.,
2014). Lithium treatment increased ratio of anti-apoptotic to pro-
apoptotic BCL-2 gene family members in lithium responders
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FIGURE 12 | Lithium may enhance neurite outgrowth via the
regulation of miR-34a. After transfection with mimic miR-34a, SH-SY5Y
cells were treated with 2mM lithium for 24 h prior to 0.5mM PQ treatment.
(A) Neurite cell number was counted using ImageJ 1.42
(http://imagej.nih.gov/ij/). (B) The average maximal neurite length for both,
the transfected and non-transfected cells were analyzed by ImageJ 1.42
(http://imagej.nih.gov/ij/). (C) Representative phase-contrast microscopy
images are shown in order to indicate neurite outgrowth distribution.
Arrowheads indicate the neurites arising from cells. Lithium pretreatment
reversed PQ induced decrease of neurite length. miR-34a mimic abolished
lithium effect on neurite length. At least 30 neurites were analyzed for each
sample. Scale bar, 50µm. The data are presented as mean ± S.E, n = 3.
(*p < 0.05 compared to control, #p < 0.05 compared to PQ treated cells
and †p < 0.05 compared to NC mimic).
patients with bipolar disorder (Lowthert et al., 2012). In our
study, PQ treatment induced apoptotic cell death and lithium
pretreatment attenuated PQ induced apoptosis.We examined the
mRNA and protein expression of BCL-2 and BAX, respectively by
qPCR andWestern blotting. It has been shown that PQ increases
p53 protein and its pro-apoptotic target gene, BAX (Yang and
Tiffany-Castiglioni, 2008). In contrast to this, p53 overexpression
decreases BCL-2 expression (Song et al., 2012).We found that PQ
decreased BCL-2/BAX ratio both in gene and protein expression
level and lithium reversed these changes. Furthermore, lithium
significantly decreased caspase-3 activity induced by PQ.
Altogether, these results confirm that anti-apoptotic effect of
lithium plays a significantly role in cytoprotection elicited by this
drug against PQ neurotoxicity in vitro.
To elucidate the regulatory mechanisms of lithium’s anti-
oxidant effect at the transcriptional level, we evaluated its
effect on gene expression of NRF2, a master modulator of
redox homeostasis, and its target genes, namely HO-1, NQO1,
and GCS (Gan and Johnson, 2014). NRF2 exerts anti-oxidant,
cytoprotective and anti-inflammatory effects via targeting a set
of battery genes, which bear ARE binding sites in their promoter
regions (Gan and Johnson, 2014). In SH-SY5Y cells, PQ decreases
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protein levels of NRF2 and its target GCS (Yang et al., 2010).
We found that lithium increased mRNA expression of NRF2
and its target genes. In addition, lithium promoted basal levels
of NRF2 in both cytosolic and nuclear fractions in SH-SY5Y
cells. Furthermore, lithium increases nuclear/cytosolic ratio of
NRF2 suggests that it significantly induces translocation of
NRF2 into the nucleus. To study the possible role of NRF2 in
lithium’s effects, we knocked down NRF2 gene using specific
siRNA. The abolishing effect of NRF2 gene silencing on lithium’s
neuroprotective and anti-oxidant effects in PQ toxicity suggest
that they are likely dependent on the transcription factor NRF2.
Lithium may also exert its protective effect against PQ via
post-trancriptional gene regulation. MicroRNAs have recently
emerged as important mediators of post-trancriptional gene
regulation (Bhalala et al., 2013). Here, we studied miR-34a,
an apoptomir, mitomir, and redoximir which targets NRF2
and BCL-2. miR-34a level was found to be increased in
postmortem cerebellar tissue from BD patients (Bavamian et al.,
2015). Lithium altered seven miRNAs including miR-34a in
20 lymphoblastoid cell lines derived from BD patients (Chen
et al., 2009a). Combined lithium and valproate treatment also
decreased miR-34a level in cerebellar granule cells (Hunsberger
et al., 2013). In addition, 4 week lithium treatment downregulated
miR-34a expression in rat hippocampus (Zhou et al., 2009).
miR-34a induces apoptosis by targeting anti-apoptotic genes
such as BCL2. It also causes cell cycle arrest by silencing
Cyclin-dependent kinase 4 (CDK4) and Cyclin-dependent kinase
(CDK6) genes and decreases cell survival (Agostini and Knight,
2014). Moreover, NRF2 and its target genes thioredoxin and
thioredoxin reductase 2 are targeted by miR-34a, thus leading
to impairment of anti-oxidant defense system (Bai et al., 2011;
Silva-Adaya et al., 2014). We found that PQ alone increased the
basal expression of miR-34a. The possible reason of this increase
may be the activation of miR-34a inducers nuclear factor of
kappa light polypeptide gene enhancer in B-cells 2 (NFkB) and
p53 transcription factors by PQ (Yang and Tiffany-Castiglioni,
2008; Yang et al., 2010; Kauppinen et al., 2013). Here, lithium
significantly decreased both basal and PQ-induced expression of
miR-34a. Currently, the mechanisms of lithium’s effect on miR-
34a expression are unknown, however, different mechanisms
including activation of various transcription factors and signaling
pathways or epigenetics factors such as DNAmethylation may be
responsible (Chiu et al., 2013; Agostini and Knight, 2014).
Next, we performed functional studies by transfection
of miR-34 specific mimic and evaluated cell viability,
neurotrophism, apoptosis, and ROS production. mRNA
expression of two validated targets of miR-34a, NRF2 and
BCL-2 significantly decreased with mimic transfection (Wang
et al., 2009; Smith-Vikos and Slack, 2012). In contrast to the
gain-of-function experiment, loss-of-function with antagomir
did not show discordance between mir-34a expression and
BDNF mRNA/protein levels. Although BDNF is predicted with
low and minimum score in only one database, this prediction
was not experimentally validated in our hands. Additionally, the
results of functional experiment with miR-34a antagomir did not
support the results of overexpression experiment. Since miRNA
overexpression represents a supraphysiological condition,
discordance between expression of a miRNA and its predicted
target may not point to a functional miRNA-target interaction
(Thomson et al., 2011). A plausible explanation for these results
is that miR-34a overexpression may indirectly inhibit BDNF
expression by suppressing the expression of CREB (one of its
validated targets), which transactivates BDNF mRNA in normal
conditions (Nair and Vaidya, 2006; Chang et al., 2011).
In addition to its classical use in BD, neurodegenerative
diseases such as PD have been proposed as other indications
for lithium therapy. We revealed two novel mechanisms for
lithium neuroprotection, namely NRF2 activation and miR-
34a suppression. The first mechanism represents an action
at the transcriptional level and the second one point to
a posttranscriptional effect. One may propose several other
different mechanisms of neuroprotection provided by lithium.
GSK-3β that activates Fyn kinase and this kinase results in
nuclear export and degradation of NRF2 (Niture et al., 2014).
Lithium inhibits GSK-3β activation and keeps NRF2 in the
nucleus. NRF2 activation may inhibit miR-34a suppressing its
inducer NFkB transcription factor (Stefanson and Bakovic,
2014).
In conclusion, since no proven medical treatment is currently
available to slow disease progression, there is a great need for
more effective novel therapeutic agents in the treatment of PD.
Lithium may be a strong candidate drug for the treatment of
PD. Here, we demonstrated the neuroprotective effect of lithium
against PQ. Additionally, we revealed two novel mechanisms
mediating lithium’s effect on neurodegeneration.
Acknowledgments
The research was supported by The Scientific and Technological
Research Council of Turkey (TÜBI˙TAK) (Grant number
212T107).
Supplementary Material
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fncel.
2015.00209/abstract
References
Agostini, M., and Knight, R. A. (2014). miR-34: from bench to bedside. Oncotarget
5, 872–881.
Allagui, M. S., Nciri, R., Rouhaud, M. F., Murat, J. C., El Feki, A., Croute, F.,
et al. (2009). Long-term exposure to low lithium concentrations stimulates
proliferation, modifies stress protein expression pattern and enhances
resistance to oxidative stress in SH-SY5Y cells. Neurochem. Res. 34, 453–462.
doi: 10.1007/s11064-008-9804-8
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., and Patel, N. K.
(2013). GDNF, NGF and BDNF as therapeutic options for neurodegeneration.
Pharmacol. Ther. 138, 155–175. doi: 10.1016/j.pharmthera.2013.01.004
Frontiers in Cellular Neuroscience | www.frontiersin.org 16 May 2015 | Volume 9 | Article 209
Alural et al. Lithium prevents paraquat toxicity
Bai, X. Y., Ma, Y., Ding, R., Fu, B., Shi, S., and Chen, X. M. (2011). miR-335 and
miR-34a Promote renal senescence by suppressing mitochondrial antioxidative
enzymes. J. Am. Soc. Nephrol. 22, 1252–1261. doi: 10.1681/ASN.2010040367
Baltazar, M. T., Dinis-Oliveira, R. J., de Lourdes Bastos, M., Tsatsakis, A. M.,
Duarte, J. A., Carvalho, F., et al. (2014). Pesticides exposure as etiological factors
of Parkinson’s disease and other neurodegenerative diseases–a mechanistic
approach. Toxicol. Lett. 230, 85–103. doi: 10.1016/j.toxlet.2014.01.039
Bavamian, S., Mellios, N., Lalonde, J., Fass, D. M., Wang, J., Sheridan, S. D., et al.
(2015). Dysregulation of miR-34a links neuronal development to genetic risk
factors for bipolar disorder. Mol. Psychiatry 20, 573–584. doi: 10.1038/mp.
2014.176
Berry, C., La Vecchia, C., andNicotera, P. (2010). Paraquat and Parkinson’s disease.
Cell Death Differ. 17, 1115–1125. doi: 10.1038/cdd.2009.217
Bhalala, O. G., Srikanth, M., and Kessler, J. A. (2013). The emerging
roles of microRNAs in CNS injuries. Nat. Rev. Neurol. 9, 328–339. doi:
10.1038/nrneurol.2013.67
Blanco-Ayala, T., Andérica-Romero, A. C., and Pedraza-Chaverri, J. (2014). New
insights into antioxidant strategies against paraquat toxicity. Free Radic. Res.
48, 623–640. doi: 10.3109/10715762.2014.899694
Blandini, F. (2013). Neural and immune mechanisms in the pathogenesis
of Parkinson’s disease. J. Neuroimmune. Pharmacol. 8, 189–201. doi:
10.1007/s11481-013-9435-y
Blesa, J., Phani, S., Jackson-Lewis, V., and Przedborski, S. (2012). Classic and new
animal models of Parkinson’s disease. J. Biomed. Biotechnol. 2012:845618. doi:
10.1155/2012/845618
Buhmann, C., Arlt, S., Kontush, A., Möller-Bertram, T., Sperber, S., Oechsner,
M., et al. (2004). Plasma and CSF markers of oxidative stress are increased in
Parkinson’s disease and influenced by antiparkinsonian medication. Neurobiol.
Dis. 15, 160–170. doi: 10.1016/j.nbd.2003.10.003
Chang, J. R., Mukerjee, R., Bagashev, A., Del Vale, L., Chabrashvili, T., Hawkins,
B. J., et al. (2011). HIV-1 Tat protein promotes neuronal dysfunction
through disruption of microRNAs. J. Biol. Chem. 286, 41125–41134. doi:
10.1074/jbc.M111.268466
Chen, H., Wang, N., Burmeister, M., and McInnis, M. G. (2009a).
MicroRNA expression changes in lymphoblastoid cell lines in response
to lithium treatment. Int. J. Neuropsychopharmacol. 12, 975–981. doi:
10.1017/S1461145709000029
Chen, P. C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W.,
et al. (2009b). Nrf2- mediated neuroprotection in the MPTP mouse model of
Parkinson’s disease: Critical role for the astrocyte. Proc. Natl. Acad. Sci. U.S.A.
106, 2933–2938. doi: 10.1073/pnas.0813361106
Chiu, C. T., Scheuing, L., Liu, G., Liao, H. M., Linares, G. R., Lin, D., et al.
(2014). The mood stabilizer lithium potentiates the antidepressant-like effects
and ameliorates oxidative stress induced by acute ketamine in a mouse model
of stress. Int. J. Neuropsychopharmacol. 18:pyu102. doi: 10.1093/ijnp/pyu102
Chiu, C. T., Wang, Z., Hunsberger, J. G., and Chuang, D. M. (2013). Therapeutic
potential of mood stabilizers lithium and valproic acid: beyond bipolar
disorder. Pharmacol. Rev. 65, 105–142. doi: 10.1124/pr.111.005512
Cousins, D. A., and Grunze, H. (2012). Interpreting magnetic resonance
imaging findings in bipolar disorder. CNS Neurosci. Ther. 18, 201–207. doi:
10.1111/j.1755-5949.2011.00280.x
Cristóvão, A. C., Choi, D. H., Baltazar, G., Beal, M. F., and Kim, Y. S. (2009).
The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-
mediated dopaminergic cell death. Antioxid. Redox Signal. 11, 2105–2118. doi:
10.1089/ars.2009.2459
D’Eustachio, P. (2011). Reactome knowledgebase of human biological pathways
and processes. Methods Mol. Biol. 694, 49–61. doi: 10.1007/978-1-60761-
977-2_4
Dias, V., Junn, E., and Mouradian, M. M. (2013). The role of oxidative stress in
Parkinson’s disease. J. Parkinsons Dis. 3, 461–491. doi: 10.3233/JPD-130230
Diniz, B. S., Machado-Vieira, R., and Forlenza, O. V. (2013). Lithium and
neuroprotection: translational evidence and implications for the treatment
of neuropsychiatric disorders. Neuropsychiatr. Dis. Treat. 9, 493–500. doi:
10.2147/NDT.S33086
Flicek, P., Ahmed, I., Amode, M. R., Barrell, D., Beal, K., Brent, S., et al. (2013).
Ensembl 2013. Nucleic Acids Res. 41, D48–D55. doi: 10.1093/nar/gks1236
Forlenza, O. V., De-Paula, V. J., and Diniz, B. S. (2014). Neuroprotective
effects of lithium: implications for the treatment of Alzheimer’s disease and
related neurodegenerative disorders. ACS Chem. Neurosci. 5, 443–450. doi:
10.1021/cn5000309
Fukumoto, T., Morinobu, S., Okamoto, Y., Kagaya, A., and Yamawaki, S.
(2001). Chronic lithium treatment increases the expression of brain-derived
neurotrophic factor in the rat brain. Psychopharmacology Berl. 158, 100–106.
doi: 10.1007/s002130100871
Gan, L., and Johnson, J. A. (2014). Oxidative damage and the Nrf2-ARE pathway
in neurodegenerative diseases. Biochim. Biophys. Acta 1842, 1208–1218. doi:
10.1016/j.bbadis.2013.12.011
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour,
M., et al. (2014). Autophagy and apoptosis dysfunction in neurodegenerative
disorders. Prog. Neurobiol. 112, 24–49. doi: 10.1016/j.pneurobio.2013.10.004
Goldman, S. M. (2014). Environmental toxins and Parkinson’s disease. Annu.
Rev. Pharmacol. Toxicol. 54, 141–164. doi: 10.1146/annurev-pharmtox-011613-
135937
Guo, C., Sun, L., Chen, X., and Zhang, D. (2013). Oxidative stress, mitochondrial
damage and neurodegenerative diseases. Neural Regen. Res. 8, 2003–2014. doi:
10.1016/j.pneurobio.2013.10.004
Hashimoto, R., Takei, N., Shimazu, K., Christ, L., Lu, B., and Chuang, D.
M. (2002). Lithium induces brain-derived neurotrophic factor and activates
TrkB in rodent cortical neurons: an essential step for neuroprotection
against glutamate excitotoxicity. Neuropharmacology 43, 1173–1179. doi:
10.1016/S0028-3908(02)00217-4
Hsu, S. D., Lin, F. M., Wu, W. Y., Liang, C., Huang, W. C., Chan, W. L., et al.
(2011). miRTarBase: a database curates experimentally validated microRNA-
target interactions. Nucleic Acids Res. 39, D163–D169. doi: 10.1093/nar/
gkq1107
Hunsberger, J. G., Fesler, E. B., Chibane, F. L., Leng, Y., Maric, D., Elkahloun,
A. G., et al. (2013). Mood stabilizer-regulated miRNAs in neuropsychiatric
and neurodegenerative diseases: identifying associations and functions. Am. J.
Trans. Res. 5, 450–464.
Jenner, P., Morris, H. R., Robbins, T. W., Goedert, M., Hardy, J., Ben-Shlomo, Y.,
et al. (2013). Parkinson’s disease–the debate on the clinical phenomenology,
aetiology, pathology and pathogenesis. J. Parkinsons Dis. 3, 1–11. doi:
10.3233/JPD-130175
Kauppinen, A., Suuronen, T., Ojala, J., Kaarniranta, K., and Salminen, A.
(2013). Antagonistic crosstalk between NF-κB and SIRT1 in the regulation
of inflammation and metabolic disorders. Cell Signal. 25, 1939–1948. doi:
10.1016/j.cellsig.2013.06.007
Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U., and Segal, E. (2007). The role of
site accessibility in microRNA target recognition. Nat. Genet. 39, 1278–1284.
doi: 10.1038/ng2135
Lee, R. C., Feinbaum, R. L., and Ambros, V. (1993). The C. elegans heterochronic
gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell
75, 843–854. doi: 10.1016/0092-8674(93)90529-Y
Litteljohn, D., Nelson, E., Bethune, C., and Hayley, S. (2011). The effects of
paraquat on regional brain neurotransmitter activity, hippocampal BDNF
and behavioural function in female mice. Neurosci. Lett. 502, 186–191. doi:
10.1016/j.neulet.2011.07.041
Lowthert, L., Leffert, J., Lin, A., Umlauf, S., Maloney, K., Muralidharan, A., et al.
(2012). Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family
members in lithium-responders one month after treatment initiation. Biol.
Mood Anxiety Disord. 2:15. doi: 10.1186/2045-5380-2-15
Malhi, G. S., Tanious, M., Das, P., Coulston, C. M., and Berk, M. (2013). Potential
mechanisms of action of lithium in bipolar disorder. Current Understanding.
CNS Drugs 27, 135–153. doi: 10.1007/s40263-013-0039-0
Martins, J. B., Bastos Mde, L., Carvalho, F., and Capela, J. P. (2013). Differential
Effects of Methyl-4-Phenylpyridinium Ion, Rotenone, and Paraquat on
Differentiated SH-SY5Y Cells. J. Toxicol. 2013:347312. doi: 10.1155/2013/
347312
Miñones-Moyano, E., Porta, S., Escaramís, G., Rabionet, R., Iraola, S., Kagerbauer,
B., et al. (2011). MicroRNA profiling of Parkinson’s disease brains identifies
early down regulation of miR-34b/c which modulate mitochondrial function.
Hum. Mol. Genet. 20, 3067–3078. doi: 10.1093/hmg/ddr210
Miranda, K. C., Huynh, T., Tay, Y., Ang, Y. S., Tam, W. L., Thomson, A. M.,
et al. (2006). A pattern-based method for the identification of MicroRNA
binding sites and their corresponding heteroduplexes. Cell 126, 1203–1217. doi:
10.1016/j.cell.2006.07.031
Frontiers in Cellular Neuroscience | www.frontiersin.org 17 May 2015 | Volume 9 | Article 209
Alural et al. Lithium prevents paraquat toxicity
Milani, P., Ambrosi, G., Gammoh, O., Blandini, F., and Cereda, C. (2013). SOD1
and DJ-1 converge at Nrf2 pathway: a clue for antioxidant therapeutic potential
in neurodegeneration. Oxid Med. Cell Longev. 2013:836760. doi: 10.1155/2013/
836760
Moretto, A., and Colosio, C. (2013). The role of pesticide exposure in the genesis of
Parkinson’s disease: epidemiological studies and experimental data. Toxicology
307, 24–34. doi: 10.1016/j.tox.2012.11.021
Nair, A., and Vaidya, V. A. (2006). Cyclic AMP response element binding protein
and brain-derived neurotrophic factor: molecules that modulate our mood?
J. Biosci. 31, 423–434. doi: 10.1007/BF02704114
Narasimhan, M., Riar, A. K., Rathinam, M. L., Vedpathak, D., Henderson, G.,
and Mahimainathan, L. (2014). Hydrogen peroxide responsive miR153
targets Nrf2/ARE cytoprotection in paraquat induced dopaminergic
neurotoxicity. Toxicol. Lett. 228, 179–191. doi: 10.1016/j.toxlet.2014.
05.020
Nelson, T. J., and Alkon, D. L. (2014). Molecular regulation of Synaptogenesis
during associative learning and memory. Brain Res. doi: 10.1016/j.brainres.
2014.11.054. [Epub ahead of print].
Niture, S. K., Khatri, R., and Jaiswal, A. K. (2014). Regulation of Nrf2-an update.
Free Radic Biol. Med. 66, 36–44. doi: 10.1016/j.freeradbiomed.2013.02.008
Park, S.W., Lee, J. G., Seo,M. K., Cho, H. Y., Lee, C. H., and Lee, J. H. (2014). Effects
of mood-stabilizing drugs on dendritic outgrowth and synaptic protein levels in
primary hippocampal neurons. Bipolar Disord. 17, 278–290. doi: 10.1111/bdi.
12262
Pasquali, L., Busceti, C. L., Fulceri, F., Paparelli, A., and Fornai, F. (2010).
Intracellular pathways underlying the effects of lithium. Behav. Pharmacol. 21,
473–492. doi: 10.1097/FBP.0b013e32833da5da
Ruby, J. G., Stark, A., Johnston,W. K., Kellis, M., Bartel, D. P., and Lai, E. C. (2007).
Evolution, biogenesis, expression, and target predictions of a substantially
expanded set of Drosophila microRNAs. Genome Res. 17, 1850–1864. doi:
10.1101/gr.6597907
Serafin, A., Foco, L., Zanigni, S., Blankenburg, H., Picard, A., Zanon,
A., et al. (2015). Overexpression of blood microRNAs 103a, 30b, and
29a in L-dopa-treated patients with PD. Neurology 84, 645–653. doi:
10.1212/WNL.0000000000001258
Silva-Adaya, D., Gonsebatt, M. E., and Guevara, J. (2014). Thioredoxin system
regulation in the central nervous system: experimental models and clinical
evidence. Oxid Med. Cell Longev. 2014:590808. doi: 10.1155/2014/590808
Smith-Vikos, T., and Slack, F. J. (2012). MicroRNAs and their roles in aging. J. Cell
Sci. 125(Pt 1), 7–17. doi: 10.1242/jcs.099200
Song, N., Boku, S., Nakagawa, S., Kato, A., Toda, H., Takamura, N., et al.
(2012). Mood stabilizers commonly restore staurosporine-induced increase
of p53 expression and following decrease of Bcl-2 expression in SH-
SY5Y cells. Prog. Neuropsychopharmacol. Biol. Psychiatry 38, 183–189. doi:
10.1016/j.pnpbp.2012.03.006
Stefanson, A. L., and Bakovic, M. (2014). Dietary regulation of Keap1/Nrf2/ARE
pathway: focus on plant-derived compounds and trace minerals. Nutrients 6,
3777–3801. doi: 10.3390/nu6093777
Stroynowska-Czerwinska, A., Fiszer, A., and Krzyzosiak, W. J. (2014). The
panorama of miRNA-mediated mechanisms in mammalian cells. Cell Mol. Life
Sci. 71, 2253–2270. doi: 10.1007/s00018-013-1551-6
Subramaniam, S. R., and Chesselet, M. F. (2013). Mitochondrial dysfunction and
oxidative stres in Parkinson’s disease. Prog. Neurobiol. 106–107, 17–32. doi:
10.1016/j.pneurobio.2013.04.004
Sun, E., and Shi, Y. (2014). MicroRNAs: small molecules with big roles in
neurodevelopment and diseases. Exp. Neurol. 268, 46–53. doi: 10.1016/j.
expneurol.2014.08.005
Thomson, D. W., Bracke, C. P., and Goodall, G. J. (2011). Experimental strategies
for microRNA target identification. Nucleic Acids Res. 39, 6845–6853. doi:
10.1093/nar/gkr330
Tufekci, K. U., Genc, S., and Genc, K. (2011). The endotoxin-induced
neuroinflammation model of Parkinson’s disease. Parkinsons Dis. 2011:487450.
doi: 10.4061/2011/487450
Tüfekci, K. U., Meuwissen, R. L., and Genç S. (2014). The role of microRNAs in
biological processes.MethodsMol. Biol. 1107, 15–31. doi: 10.1007/978-1-62703-
748-8_2
Vallelunga, A., Ragusa, M., DiMauro, S., Iannitti, T., Pilleri, M., Biundo, R., et al.
(2014). Identification of circulating microRNAs for the differential diagnosis
of Parkinson’s disease and multiple systematrophy. Front. Cell Neurosci. 8:156.
doi: 10.3389/fncel.2014.00156
Wang, X., Liu, P., Zhu, H., Xu, Y., Ma, C., Dai, X., et al. (2009). miR-
34a, a microRNA up-regulated in a double transgenic mouse model of
Alzheimer’s disease, inhibits bcl2 translation. Brain Res. Bull. 80, 268–273. doi:
10.1016/j.brainresbull.2009.08.006
Yang, W., and Tiffany-Castiglioni, E. (2008). Paraquat-induced apoptosis in
human neuroblastoma SH-SY5Y cells: involvement of p53 and mitochondria.
J. Toxicol. Environ. Health A 71, 289–299. doi: 10.1080/15287390701738467
Yang, W., Tiffany-Castiglioni, E., Lee, M. Y., and Son, I. H. (2010).
Paraquat induces cyclooxygenase-2, COX-2) implicated toxicity in
human neuroblastoma SH-SY5Y cells. Toxicol. Lett. 199, 239–246. doi:
10.1016/j.toxlet.2010.09.005
Yang,W., Yan, Z., Hongjing, Z., Dexiang, L., Zengxun, L., Xiaojing, C., et al. (2014).
The toxic effect of lithium ion on neurons, PC12 cells) and Aâ42 molecules.
Biol. Trace Elem. Res. 159, 410–415. doi: 10.1007/s12011-014-9949-z
Zhou, R., Yuan, P., Wang, Y., Hunsberger, J. G., Elkahloun, A., Wei, Y., et al.
(2009). Evidence for selective microRNAs and their effectors as common long-
term targets for the actions of mood stabilizers. Neuropsychopharmacology 34,
1395–1405. doi: 10.1038/npp.2008.131
Zuo, L., and Motherwell, M. S. (2013). The impact of reactive oxygen species and
genetic mitochondrial mutations in Parkinson’s disease. Gene 532, 18–23. doi:
10.1016/j.gene.2013.07.085
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Alural, Ozerdem, Allmer, Genc and Genc. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 18 May 2015 | Volume 9 | Article 209
